According to Zacks, “Indivior PLC operates as a specialty pharmaceutical company. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine intoxication and co-occurring conditions, such as schizophrenia. The Company markets and promotes SUBOXONE (buprenorphine and naloxone) Sublingual Film, SUBOXONE (buprenorphine and naloxone) Sublingual Tablet, and SUBUTEX (buprenorphine) Sublingual Tablet, each buprenorphine-based treatment for opioid. Indivior PLC is based in United States. “
Shares of INDIVIOR PLC SPON ADR EA REPR 5 (NASDAQ:INVVY) traded up 0.8539% on Tuesday, hitting $18.6378. 369 shares of the stock traded hands. The stock has a 50-day moving average price of $19.18 and a 200 day moving average price of $19.53. INDIVIOR PLC SPON ADR EA REPR 5 has a 52 week low of $9.29 and a 52 week high of $23.30. The firm’s market cap is $2.69 billion.
Receive News & Ratings for INDIVIOR PLC SPON ADR EA REPR 5 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INDIVIOR PLC SPON ADR EA REPR 5 and related companies with our FREE daily email newsletter.